BL-2030

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameBL-2030
Drug Alias NameBL-2030
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionC-C motif chemokine 2 inhibitorsC-C chemokine receptor type 2 modulators
TargetsC-C chemokine receptor type 2C-C motif chemokine 2
Therapy Area/IndicationsAutoimmune DiseasesProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBioRap Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiolinerx LtdBioRap Technologies Ltd
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A